Catalyst Biosciences (NASDAQ:CBIO) Trading Up 5.8%

Catalyst Biosciences Inc (NASDAQ:CBIO) shares were up 5.8% on Monday . The company traded as high as $7.37 and last traded at $7.32, approximately 103,997 shares changed hands during trading. A decline of 11% from the average daily volume of 116,859 shares. The stock had previously closed at $6.92.

A number of research analysts recently weighed in on CBIO shares. ValuEngine raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st. Zacks Investment Research raised shares of Catalyst Biosciences from a “hold” rating to a “buy” rating and set a $8.50 price target on the stock in a research report on Tuesday, August 6th. Five investment analysts have rated the stock with a buy rating, The company has a consensus rating of “Buy” and an average price target of $22.88.

The company has a market capitalization of $88.59 million, a P/E ratio of -2.71 and a beta of 2.10. The company has a quick ratio of 15.83, a current ratio of 15.83 and a debt-to-equity ratio of 0.02. The business’s 50-day moving average is $8.01 and its two-hundred day moving average is $8.32.

Catalyst Biosciences (NASDAQ:CBIO) last announced its quarterly earnings data on Thursday, August 1st. The biopharmaceutical company reported ($1.15) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.01. Analysts predict that Catalyst Biosciences Inc will post -4.83 EPS for the current year.

A number of hedge funds have recently made changes to their positions in the business. Private Advisors LLC raised its position in Catalyst Biosciences by 5.9% in the first quarter. Private Advisors LLC now owns 26,989 shares of the biopharmaceutical company’s stock worth $138,000 after acquiring an additional 1,495 shares during the period. A.R.T. Advisors LLC raised its position in Catalyst Biosciences by 16.0% in the second quarter. A.R.T. Advisors LLC now owns 22,828 shares of the biopharmaceutical company’s stock worth $168,000 after acquiring an additional 3,150 shares during the period. Tower Research Capital LLC TRC raised its position in Catalyst Biosciences by 2,288.8% in the second quarter. Tower Research Capital LLC TRC now owns 4,037 shares of the biopharmaceutical company’s stock worth $29,000 after acquiring an additional 3,868 shares during the period. Geode Capital Management LLC raised its position in Catalyst Biosciences by 3.9% in the fourth quarter. Geode Capital Management LLC now owns 144,175 shares of the biopharmaceutical company’s stock worth $1,137,000 after acquiring an additional 5,405 shares during the period. Finally, Jane Street Group LLC bought a new stake in Catalyst Biosciences in the second quarter worth about $107,000. 58.98% of the stock is currently owned by institutional investors and hedge funds.

About Catalyst Biosciences (NASDAQ:CBIO)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing medicines to address hematology indications. Its product pipeline includes marzeptacog alfa, a Factor VIIa variant that is in a Phase II/III clinical trial for the prophylactic treatment of individuals with severe hemophilia A and B with inhibitors.

See Also: Overbought

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.